Blog Posts
October 18, 2023

From Biochemistry to Guitars: Unplugged with Dr. Mark Gramling!

Blog Posts
October 18, 2023

From Biochemistry to Guitars: Unplugged with Dr. Mark Gramling!

Author
Neneh Vannitamby, MD
Medical Writer

Hey LARVOL fam! Today, we've managed to grab some precious moments with our very own VP Oncology, Dr. Mark Gramling. We've got science, guitars, and comedy skits on the docket, so let's dive right in!

Dr. Mark Gramling - VP Oncology at LARVOL

LARVOL: Could you briefly introduce yourself and describe your role at LARVOL?

Dr. Mark Gramling: I’ve been with LARVOL in two separate tentures. For my first, I focused on developing services supporting healthcare and clinical trials. In my second tenure, I’ve focused on building and developing existing and new products in oncology.

LARVOL: Every person's journey is unique. Can you share with us the story of how you landed in the field of oncology and at LARVOL specifically?

Dr. Mark Gramling: I like to describe myself as a “recovering scientist”. For my undergrad, I studied biochemistry and microbiology and figured if I did that I would pursue a PhD in pathology examining disease mechanisms. I found the preclinical models of oncology the most intriguing and chose to continue pursuing that in my postdoctoral studies. After my post-doctoral studies, I saw a job posting for supporting market intelligence reports that was originally part-time for LARVOL - and I guess I’ve never turned back.

 

LARVOL: What do you enjoy most about your role at LARVOL and how has it impacted your professional journey?

Dr. Mark Gramling: There is obviously the remote element - of which LARVOL has been innovative for many years. I love being able to connect to a global team and being part of a company with a team that is always exploring, experimenting, and growing to try new things to support our customers is particularly fulfilling.

 

LARVOL: In an industry as fast-paced as ours, it's important to have strong motivation. What personally motivates you in your role at LARVOL, and how do you keep that motivation alive in the face of challenges?

Dr. Mark Gramling: Whether a strength or a weakness, I always think about people and my teams first. When you know we’re all dependent upon each other across 10 different time zones to achieve a collective goal, it’s hard not to be motivated by that.

 

LARVOL: At LARVOL, we know the importance of work-life balance. Outside of your professional role, what unique hobby or interest might surprise your colleagues at LARVOL?

Dr. Mark Gramling: We obviously use both virtual reality but also video conferences, so it wouldn’t surprise my colleagues that I have guitars hanging up all over my house. As much as I try to tell a joke or two in meetings, they might also be surprised how much time I spend delving into the history and the latest in stand up and sketch comedy.

 

There you have it! A blend of science, music, and humor – that’s Dr. Mark Gramling for you. Stay tuned for more behind-the-scenes LARVOL chats with our fantastic team!

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.